Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Cash from Financing Activities (2021 - 2025)

Core Scientific's Cash from Financing Activities history spans 5 years, with the latest figure at -$21.8 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 103.65% year-over-year to -$21.8 million; the TTM value through Dec 2025 reached -$63.1 million, down 107.7%, while the annual FY2025 figure was -$63.1 million, 107.7% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$21.8 million at Core Scientific, down from -$5.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $598.2 million in Q4 2024 and bottomed at -$45.1 million in Q3 2022.
  • The 5-year median for Cash from Financing Activities is $10.0 million (2021), against an average of $81.1 million.
  • The largest annual shift saw Cash from Financing Activities crashed 148.04% in 2023 before it soared 5424.49% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $170.2 million in 2021, then crashed by 77.63% to $38.1 million in 2022, then plummeted by 148.04% to -$18.3 million in 2023, then surged by 3369.23% to $598.2 million in 2024, then crashed by 103.65% to -$21.8 million in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Cash from Financing Activities are -$21.8 million (Q4 2025), -$5.3 million (Q3 2025), and -$31.8 million (Q2 2025).